Atlas Trials

Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer

Clinical trial NCT02593929 · WITHDRAWN

Trial details

NCT number
NCT02593929
Sponsor
University of Pittsburgh
Status
WITHDRAWN
Phase
Early Phase 1
Study type
INTERVENTIONAL
Head and Neck Squamous Cell Carcinoma
Start date
2017-01-01
Primary completion
2018-01-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.